Phathom Pharmaceuticals Inc

NASDAQ:PHAT  
18.16
-0.54 (-2.89%)
Regulatory, Earnings Announcements

Phathom Pharmaceuticals Reports Third Quarter 2021 Results And Provides Key Clinical, Regulatory, And Business Updates

Published: 11/08/2021 14:11 GMT
Phathom Pharmaceuticals Inc (PHAT) - Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates.
Phathom Pharmaceuticals Inc - U.S. Launch for Both Vonoprazan-based Treatment Regimens for H. Pylori Anticipated in Second Half of 2022.
Phathom Pharmaceuticals Inc - As of Sep 30, 2021, Cash and Cash Equivalents Were $224.6 Million and Are Expected to Meet Requirements Into Mid-2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.99

Next Quarter Revenue Guidance is expected to be $0.32 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.